Brought to you by 
NantKwest nets $222mm in IPO
04 Aug 2015
Executive Summary
NantKwest Inc (formerly Conkwest; natural killer (NK) cells for cancer, infectious disease, and immune disorders) netted $222mm in its IPO of 9.5mm shares (including the overallotment) at $25, above its planned terms of 7mm shares for $20-23. Existing stockholders including Franklin Templeton and NantKwest CEO Patrick Soon-Shiong, MD, agreed to buy $55.5mm in IPO shares. In a separate private placement, NantKwest raised $17mm from Celgene.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Gene Therapy, Cell Therapy
-
Large Molecule
- Antibodies
Deal Status
- Final
Deal Type
-
Financing
- IPO
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
NantKwest nets $222mm in IPO
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice